Acute inflammatory demyelinating polyradiculoneuropathy

disease
On this page

Also known as acute idiopathic demyelinating polyneuropathyacute inflammatory demyelinating polyradiculopathyacute inflammatory polyneuropathyAIDPGBS, acute inflammatory demyelinating polyradiculoneuropathic formGuillain-Barre syndrome, acute inflammatory demyelinating polyradiculoneuropathic formGuillain-Barré syndrome, acute inflammatory demyelinating polyradiculoneuropathic form

Summary

Acute inflammatory demyelinating polyradiculoneuropathy (MONDO:0020347) is a disease and 3 clinical trials. A subtype of Guillain-Barre syndrome — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Prevalence: 1-9 / 100 000 (Europe) [Orphanet-validated]
  • Phenotypes (HPO): 13
  • Clinical trials: 3

Clinical features

Epidemiology

Prevalence records

1 prevalence record(s), Orphanet:

TypeClassValueGeographyValidation
Point prevalence1-9 / 100 0003.1EuropeValidated

Signs & symptoms

Clinical features (HPO)

13 HPO clinical features (Orphanet curated; top 13 by frequency):

HPO IDTermFrequency
HP:0007131Acute demyelinating polyneuropathyObligate (100%)
HP:0001265HyporeflexiaFrequent (30-79%)
HP:0001290Generalized hypotoniaFrequent (30-79%)
HP:0001954Recurrent feverFrequent (30-79%)
HP:0002307DroolingFrequent (30-79%)
HP:0002317Unsteady gaitFrequent (30-79%)
HP:0003445EMG: neuropathic changesFrequent (30-79%)
HP:0005335Sleepy facial expressionFrequent (30-79%)
HP:0009053Distal lower limb muscle weaknessFrequent (30-79%)
HP:0012534DysesthesiaFrequent (30-79%)
HP:0031162Impaired oropharyngeal swallow responseFrequent (30-79%)
HP:0003383Onion bulb formationOccasional (5-29%)
HP:0002066Gait ataxiaExcluded (0%)

Identifiers

Disease identifiers

FieldValue
Canonical nameacute inflammatory demyelinating polyradiculoneuropathy
Mondo IDMONDO:0020347
Orphanet98916
ICD-111196874419
NCITC116926
UMLSC4551910
MedGen1648220
GARD0016873
Is cancer (heuristic)no

Also known as: acute idiopathic demyelinating polyneuropathy · acute inflammatory demyelinating polyradiculopathy · acute inflammatory polyneuropathy · AIDP · GBS, acute inflammatory demyelinating polyradiculoneuropathic form · Guillain-Barre syndrome, acute inflammatory demyelinating polyradiculoneuropathic form · Guillain-Barré syndrome, acute inflammatory demyelinating polyradiculoneuropathic form

Disease family

This is a subtype of Guillain-Barre syndrome. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorderautoimmune disorder of the nervous systemautoimmune disorder of peripheral nervous systemGuillain-Barre syndromeacute inflammatory demyelinating polyradiculoneuropathy

Related subtypes (10): Guillain-Barre syndrome, familial, pharyngeal-cervical-brachial variant of Guillain-Barre syndrome, paraparetic variant of Guillain-Barre syndrome, acute pure sensory neuropathy, autoimmune autonomic ganglionopathy, acute sensory ataxic neuropathy, facial diplegia with paresthesias, acute motor and sensory axonal neuropathy, acute motor axonal neuropathy, polyneuropathy, inflammatory demyelinating, chronic

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified3

Top trials by phase / activity

NCTPhaseStatusTitle
NCT07333196Not specifiedNOT_YET_RECRUITINGTongji NADs Cohort
NCT01469858Not specifiedUNKNOWNPerception and Multisensory Integration in Neurological Patients Using fMRI
NCT02722070Not specifiedUNKNOWNProcessing Integration in Neurological Patients Using fMRI

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.